{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T21:15:24Z","timestamp":1771103724177,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Long-term survivors of cutaneous malignant melanoma (CMM) risk subsequent malignancies due to both host-related and environmental risk factors. This retrospective population-based study differentially assesses the risk of synchronous and metachronous cancers in a cohort of CMM survivors stratified by sex.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The cohort study (1999\u20132018) included 9,726 CMM survivors (M\u2009=\u20094,873, F\u2009=\u20094,853) recorded by the cancer registry of all 5,000,000 residents in the Italian Veneto Region. By excluding subsequent CMM and non-CMM skin cancers, the incidence of synchronous and metachronous malignancies was calculated according to sex and tumor site, standardizing for age and calendar year. The Standardized Incidence Ratio (SIR) was calculated as the ratio between the number of subsequent cancers among CMM survivors and the expected number of malignancies among the regional population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Irrespective of the site, the SIR for synchronous cancers increased in both sexes (SIR\u2009=\u20091.90 in males and 1.73 in females). Both sexes also demonstrated an excess risk for synchronous kidney\/urinary tract malignancies (SIR\u2009=\u20096.99 in males and 12.11 in females), and women had an increased risk of synchronous breast cancer (SIR\u2009=\u20091.69). CMM male survivors featured a higher risk of metachronous thyroid (SIR\u2009=\u20093.51, 95% CI [1.87, 6.01]), and prostate (SIR\u2009=\u20091.35, 95% CI [1.12, 1.61]) malignancies. Among females, metachronous cancers featured higher SIR values than expected: kidney\/urinary tract (SIR\u2009=\u20092.27, 95% CI [1.29, 3.68]), non-Hodgkin\u2019s lymphoma (SIR\u2009=\u20092.06, 95% CI [1.24, 3.21]), and breast (SIR\u2009=\u20091.46, 95% CI [1.22, 1.74]). Females had an overall increased risk of metachronous cancers in the first 5\u2009years after CMM diagnosis (SIR\u2009=\u20091.54 at 6\u201311\u2009months and 1.37 at 1\u20135\u2009years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Among CMM survivors, the risk of metachronous non-skin cancers is higher than in the general population and differs significantly by sex. These results encourage sex-tailored interventions for metachronous secondary cancer prevention.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1195458","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:41:06Z","timestamp":1686897666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Synchronous and metachronous multiple primary cancers in melanoma survivors: a gender perspective"],"prefix":"10.3389","volume":"11","author":[{"given":"Stefano","family":"Guzzinati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Buja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Grotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariagiovanna","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Bovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Del Fiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saveria","family":"Tropea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Dall\u2019Olmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo R.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Mocellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Rugge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","article-title":"Malignant melanoma: skin cancer-diagnosis, prevention, and treatment","volume":"30","author":"Ahmed","year":"2020","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/medsci9040063","article-title":"Epidemiology of melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"ref3","unstructured":"2021"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.jaad.2011.04.033","article-title":"Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin","volume":"65","author":"Balamurugan","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2014.02.007","article-title":"The risk of developing a second primary cancer in melanoma patients: a comprehensive review of the literature and meta-analysis","volume":"75","author":"Caini","year":"2014","journal-title":"J Dermatol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e000172","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple primary tumours: challenges and approaches, a review","volume":"2","author":"Vogt","year":"2017","journal-title":"ESMO Open"},{"key":"ref7","unstructured":"2022"},{"key":"ref8","unstructured":"2022"},{"key":"ref9","first-page":"i\u2013xix, 1","article-title":"Veneto Region, Italy. Health system review","volume":"14","author":"Toniolo","year":"2012","journal-title":"Health Syst Transit"},{"key":"ref10","volume-title":"Airtum Cancer Registration Handbook","author":"Ferretti","year":"2009"},{"key":"ref11","first-page":"629384","article-title":"Multiple primary tumors over a lifetime","volume":"33","author":"Copur","year":"2019","journal-title":"Oncol Williston Park N"},{"key":"ref12","first-page":"219","article-title":"Summary: multiple primary cancers in Connecticut, 1935-82","volume":"68","author":"Curtis","year":"1985","journal-title":"Natl Cancer Inst Monogr"},{"key":"ref13","first-page":"1","article-title":"Statistical methods in cancer research. Volume II--the design and analysis of cohort studies","volume":"82","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"ref15","unstructured":"2023"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/1471-2407-13-287","article-title":"Cancer survivors in Switzerland: a rapidly growing population to care for","volume":"13","author":"Herrmann","year":"2013","journal-title":"BMC Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1200\/JCO.2012.41.8681","article-title":"Second malignant neoplasms: assessment and strategies for risk reduction","volume":"30","author":"Wood","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/archdermatol.2010.2","article-title":"Increased risk of second primary cancers after a diagnosis of melanoma","volume":"146","author":"Bradford","year":"2010","journal-title":"Arch Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/CMR.0b013e3282fafd0a","article-title":"The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian network of Cancer registries)","volume":"18","author":"Crocetti","year":"2008","journal-title":"Melanoma Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1046\/j.1365-2133.2001.04507.x","article-title":"Risk of second primary malignancies in patients with cutaneous melanoma","volume":"145","author":"Schmid-Wendtner","year":"2001","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-4632.2005.02640.x","article-title":"The association between malignant melanoma and noncutaneous malignancies","volume":"45","author":"Wu","year":"2006","journal-title":"Int J Dermatol"},{"key":"ref22","first-page":"9","article-title":"Methods","volume-title":"New Malignancies among Cancer Survivors: SEER Cancer Registries, 1973\u20132000","author":"Curtis","year":"2006"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1586\/14737140.6.5.657","article-title":"High- and low-penetrance cutaneous melanoma susceptibility genes","volume":"6","author":"Fargnoli","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1001\/archdermatol.2011.1133","article-title":"Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer","volume":"147","author":"Yang","year":"2011","journal-title":"Arch Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"6340","DOI":"10.3390\/cancers13246340","article-title":"Pan-genomic sequencing reveals actionable CDKN2A\/2B deletions and Kataegis in anaplastic thyroid carcinoma","volume":"13","author":"Stenman","year":"2021","journal-title":"Cancers"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamaoto.2014.78","article-title":"Increased melanoma risk in individuals with papillary thyroid carcinoma","volume":"140","author":"Oakley","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.bjc.6602654","article-title":"Second primary cancers among 109 000 cases of non-Hodgkin\u2019s lymphoma","volume":"93","author":"Brennan","year":"2005","journal-title":"Br J Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/1097-0142(19910401)67:7<2002::AID-CNCR2820670729>3.0.CO;2-E","article-title":"Second cancers following non-Hodgkin\u2019s lymphoma","volume":"67","author":"Travis","year":"1991","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/1097-0142(20010215)91:4<874::AID-CNCR1076>3.0.CO;2-O","article-title":"Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma","volume":"91","author":"Goggins","year":"2001","journal-title":"Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(81)92359-X","article-title":"Malignant melanoma in renal-transplant recipients","volume":"317","author":"Greene","year":"1981","journal-title":"Lancet Lond Engl"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid cancers after bone marrow transplantation","volume":"336","author":"Curtis","year":"1997","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/COH.0000000000000327","article-title":"Evolving epidemiology of HIV-associated malignancies","volume":"12","author":"Shiels","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-2350-15-59","article-title":"A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma","volume":"15","author":"Frigerio","year":"2014","journal-title":"BMC Med Genet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/gcc.20893","article-title":"Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas","volume":"50","author":"Guney","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"ref35","first-page":"541","article-title":"Abnormalities of the short arm of chromosome 9 with partial loss of material in hematological disorders","volume":"1","author":"Pollak","year":"1987","journal-title":"Leukemia"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"10557","DOI":"10.1073\/pnas.89.21.10557","article-title":"Homozygous deletions within human chromosome band 9p21 in melanoma","volume":"89","author":"Fountain","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ijc.20322","article-title":"Association between female breast cancer and cutaneous melanoma","volume":"111","author":"Goggins","year":"2004","journal-title":"Int J Cancer"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/jnci\/92.15.1260","article-title":"High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families","volume":"92","author":"Borg","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1038\/sj.onc.1206444","article-title":"Melanoma etiology: where are we?","volume":"22","author":"Tucker","year":"2003","journal-title":"Oncogene"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3390\/cancers12082228","article-title":"Design and testing of a custom melanoma next generation sequencing panel for analysis of circulating tumor DNA","volume":"12","author":"Diefenbach","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1195458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:41:13Z","timestamp":1686897673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1195458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":41,"alternative-id":["10.3389\/fpubh.2023.1195458"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1195458","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1195458"}}